Where results make sense

About us   |   Why use us?   |   Reviews   |   PR   |   Contact us

Topic: Sanofi-Aventis

    Note: these results are not from the primary (high quality) database.

Ads by Google

In the News (Tue 29 Dec 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

Sanofi-Aventis - Wikipedia, the free encyclopedia The Aventis Prizes are managed by the Royal Society, the UK national academy of science, and the Aventis Foundation, a German charitable trust established in 1996 as the Hoechst Foundation with an endowment of €50 million. Aventis was formed in 1999 when Rhône-Poulenc S.A. merged with Hoechst Marion Roussel, which itself was formed from the merger of Hoechst AG with Roussel Uclaf and Marion Merrell Dow. The Aventis Prizes for Science Books, which celebrate the very best in popular science writing for adults and children, have grown to be one of the world's most prestigious non-fiction literary prizes. en.wikipedia.org /wiki/Sanofi-Aventis   (501 words)

BBC NEWS Business Aventis formally rejects Sanofi Sanofi's pipeline, the drugs it has in development, is thought in some circles to be stronger than its counterpart, justifying a valuation which is about the same as Aventis' despite the latter having twice the sales. Sanofi wants to buy Aventis partly to avoid becoming a target itself after a key shareholder pact between L'Oreal and Total expires in December, who together own 44% of Sanofi. A Sanofi-Aventis merger would form the world's third-biggest drug company. news.bbc.co.uk /go/click/rss/0.91/public/-/1/hi/business/3497953.stm   (283 words)

Boston.com / Business / Sanofi board ponders hostile Aventis bid Sanofi and Aventis have repeatedly denied that talks are under way on a merger of equals -- giving extra weight to reports that Sanofi is preparing an unsolicited offer. Sanofi has about half the revenue but roughly the same market capitalization as Aventis -- a disparity which could favor the smaller firm if a deal is concluded soon. Sanofi was continuing to discuss the terms of the offer with its two biggest shareholders, L'Oreal and Total, late Sunday. www.boston.com /business/articles/2004/01/25/sanofi_board_ponders_hostile_aventis_bid   (392 words)

Welcome to sanofi pasteur Corporate Website : Grippe aviaire - 15/09/2005 Sanofi pasteur, the vaccines business of the sanofi-aventis Group, sold nearly a billion doses of vaccine in 2004, making it possible to protect more than 500 million people across the globe, which is about 1.4 million per day. Sanofi pasteur was awarded 35% of the annual interpandemic vaccine supply. The agreement provides for additional fees to be paid to sanofi pasteur for storage of the vaccine as well as for formulation and filling of the vaccine upon government request. www.sanofipasteur.com /sanofi-pasteur/front/templates/vaccinations-travel-health-vaccine-aventis-pasteur.jsp?〈=EN&codeRubrique=13&codePage=PR_15092005   (1120 words)

BBC NEWS Business Aventis and Sanofi set for merger The synergies are persuasive; Aventis has a powerful presence in the huge US market, but a relatively weak inventory of new drugs -- called a drugs pipeline in the pharmaceutical industry -- while Sanofi is the opposite; a full pipeline, but a poor presence in the US. Sanofi wants to buy Aventis partly to avoid becoming a target itself after a key shareholder pact between L'Oreal and Total expires in December. France's Prime Minister Jean-Pierre Raffarin said that: "The choice of a merger between Sanofi and Aventis will allow the preservation of decision centres and jobs in France and Europe, and is in line with a strategic interest". news.bbc.co.uk /1/hi/business/3658639.stm   (412 words)

Sanofi launches hostile bid for Aventis - Financial Times - MSNBC.com Sanofi and Aventis shares were both suspended on Monday morning, while L'Oréal and Total shares both fell in early trading in Paris. Sanofi said it had agreed a €12 billion credit facility with BNP Paribas and Merrill Lynch, which are also acting as its advisers on the bid, to fund the cash part of the deal and refinance some of Aventis's debt.  If Sanofi loses the Plavix case its shares are expected to fall sharply, making Aventis keener to wait until after the case is settled before agreeing to a merger. www.msnbc.msn.com /id/4062269   (701 words)

Bloomberg.com: Top Worldwide Sanofi is more profitable, with an operating margin, or profit as a percentage of sales, of 37 percent in 2003, compared with Aventis's 21 percent. Sanofi would gain Aventis's Allegra allergy pill and blood- thinner Lovenox. Sanofi itself was about to be become vulnerable to a takeover with the expiration in December of an agreement between its two biggest shareholders, Total SA and L'Oreal SA, that required each to maintain a stake of at least 20 percent in the drug company. quote.bloomberg.com /apps/news?pid=10000087&refer=top_world_news&sid=abxIQIlWEsGw   (1036 words)

Sanofi-Aventis buys stake in Zentiva - Boston.com Sanofi- Aventis SA, the world's third-largest pharmaceutical company, said Monday it bought a 25 percent stake in Czech drugmaker Zentiva for 430 million euros ($515 million). The deal is the first acquisition by Sanofi-Aventis since its creation in an August 2004 takeover of Aventis by rival Sanofi-Synthelabo. Zentiva management will continue to own 5.9 percent of the company's capital, Sanofi-Aventis said. www.boston.com /business/articles/2006/03/27/sanofi_aventis_buys_stake_in_zentiva   (321 words)

Welcome to sanofi pasteur in Canada : Welcome to sanofi pasteur in Canada Sanofi pasteur is the vaccines business of the sanofi-aventis Group, the third largest pharmaceutical company in the world. Aventis Pasteur, the vaccine division of the sanofi-aventis Group, changes its name to sanofi pasteur. We are sanofi pasteur in Canada, the country's largest vaccine company with a proud heritage and commitment to public health. www.sanofi-pasteur.ca /sanofi-pasteur-ca/front/pages/vaccination-immunology-vaccines-aventis-pasteur.jsp   (118 words)

Aventis accepts Sanofi's $65-bn bid- The Times of India Sanofi is offering five of its shares, plus 120 euros ($142), for each six shares of Aventis stock, said one person close to the negotiations. Separately, Sanofi's bid for Aventis may be approved by the EC, according to one person close to the situation. The higher offer represented a shift for both Sanofi, which had refused to alter its $60 billion bid for Aventis, made in January, and for Aventis, which had insisted that it would be a stronger company if it did not combine with Sanofi. timesofindia.indiatimes.com /articleshow/641036.cms   (312 words)

Bloomberg.com: Europe Dec. 15 (Bloomberg) -- Sanofi-Aventis SA, the world's third-largest drugmaker, said an early trial suggests that the experimental bird flu vaccine it's trying to develop to help avert a pandemic is safe and effective. Sanofi and rivals drugmakers GlaxoSmithKline Plc, Akzo Nobel NV and Chiron Corp. are racing to develop a vaccine as governments try to prepare for a possible bird flu pandemic. Sanofi's experimental vaccine provoked a good immune system response in a significant number of volunteers, the company said today in an e-mailed statement. www.bloomberg.com /apps/news?pid=10000085&sid=a9ln5cCJ4vlA&refer=europe   (448 words)

Forbes.com: UPDATE 6-Sanofi wins Aventis with sweetened takeover bid Sanofi was advised by Merrill Lynch and BNP Paribas while Goldman Sachs, Morgan Stanley and Rothschild advised Aventis. Aventis shares have recently traded at a substantial premium to Sanofi's original offer as investors bet Novartis would trump it or Sanofi would put more cash on the table. Dealers and analysts said Sanofi may have given too much of the synergy benefit from the deal to Aventis investors, thereby reducing the value of the offer to Sanofi shareholders. www.forbes.com /newswire/2004/04/26/rtr1347229.html   (988 words)

CBC News: Sanofi, Aventis reach merger deal Sanofi is the maker of anti-thrombosis drug Lovenox, while Aventis is the developer of Plavix, a blood thinner. In the wake of the first Sanofi hostile bid, Aventis tried to negotiate a friendly takeover deal with Switzerland's Novartis, which has now withdrawn from the race. Aventis turned down Sanofi's original Jan. 26 offer for $55.2 billion US in cash and shares. www.cbc.ca /stories/2004/04/26/business/sanofiaventis_040426   (193 words)

Sanofi-aventis Announces Strong Growth In 2005 The material impacts of the application of purchase accounting to the Aventis acquisition and of restructuring charges on the 2005 first-half consolidated income statement are as follows: * (a) A charge arising from the workdown of acquired inventories remeasured at fair value. As the acquisition of Aventis took place on August 20, 2004, the structure of the Group is not directly comparable year on year. The material impacts of the application of purchase accounting to the acquisition are as follows: - charges arising from the remeasurement of Aventis inventories at fair value, net of tax; - amortization/impairment expense generated by the remeasurement of Aventis intangible assets, net of tax; - any impairment charged against the goodwill arising on the acquisition. www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-31-2005/0004096986&EDATE=   (3171 words)

Aventis accepts sweetened Sanofi bid - International Business - MSNBC.com Dehecq talked down Aventis’ drug development pipeline, while Aventis filed lawsuits against Sanofi on both sides of the Atlantic and warned investors that a U.S. patent challenge to it’s blockbuster blood thinner, Plavix, was a time bomb that could slash its share price. Aventis and Sanofi would have equal representation in each committee. The deal between Sanofi and Aventis ends three months of bitter verbal warfare between the two companies. www.msnbc.msn.com /id/4830334   (760 words)

Investor's Business Daily: Breaking News Sanofi has raised the value of the euro47 billion ($55 billion) unsolicited bid it launched on Jan 26, while Novartis had also put in a firm offer to Aventis directors, according to the sources. The Aventis board gathered in Paris the day after Sanofi's board held its own emergency meeting, at which they discussed raising their bid for Sanofi, maker of blood thinner Plavix. Landau told Dehecq that a sweetened bid from Sanofi would be given serious consideration by the Aventis board, said a person familiar with the discussions, who asked not to be named. www.investors.com /breakingnews.asp?journalid=20864426&brk=1   (608 words)

FT.com - Lex: Sanofi-Aventis Sanofi also hopes, perhaps optimistically, to position Acomplia as an effective anti-diabetes agent, thereby gaining access to a market 20 times the size of that for obesity drugs. Deutsche Bank (NYSE:DB) reckons 40 per cent of Sanofi's current operating profit faces a threat from generic drugs between 2008-12. In December, Pfizer (NYSE:PFE) 's successful defence of its patent on a drug facing generic competition boosted hopes for Sanofi, which faces two similar cases this year. us.ft.com /ftsuperpage/superpage.php?news_id=fto013120060451215357&...   (217 words)

CNN.com - Sanofi targets Aventis for merger - Jan. 26, 2004 Sanofi is also offering an alternative bid of 35 of its shares for 34 Aventis shares, which was equal to 60.43 euros per share, compared to Aventis' closing price on Friday of 57.55. The AMF regulator said in a statement Monday Sanofi was offering five of its shares for six Aventis shares plus 69 euros in cash, valuing Aventis at around $60 billion. A deal involving Sanofi and Aventis would create one of the world's biggest healthcare firms. www.cnn.com /2004/BUSINESS/01/26/france.sanofi.aventis.reut   (338 words)

C&EN: LATEST NEWS - SANOFI UPS OFFER TO WIN AVENTIS As the world's number three drug company, Sanofi-Aventis will be larger than Novartis, the Swiss firm that Aventis had tried to enlist as a white knight merger alternative to Sanofi. The increasingly acrimonious three-month effort of French drug company Sanofi-Synthélabo to take over Aventis concluded last week when an improved second offer won acceptance by Aventis directors. And many analysts see looming cultural clashes between Sanofi and Aventis units, particularly in RandD, which might make Dehecq's job of cutting costs that much more difficult. pubs.acs.org /cen/news/8218/8218notw4.html   (409 words)

Sanofi Aventis "buy" newratings.com Sanofi Aventis has signed this deal to compete with the alliance formed by Teva and Barr to market their version of Allegra, the analysts say. LONDON, September 13 (newratings.com) - Analysts at Dryden Financial maintain their "buy" rating on Sanofi Aventis (SNW.ETR). Sanofi Synthelabo quote - chart - all headlines - analyst actions - add to watchlist www.newratings.com /analyst_news/article_1013486.html   (241 words)

Welcome to sanofi pasteur Corporate Website : Welcome to sanofi pasteur in the U.S. Welcome to sanofi pasteur in the U.S. Sanofi pasteur, the vaccines business of sanofi-aventis Group, is the largest company in the world devoted entirely to vaccines. Sanofi pasteur, the vaccines business of the sanofi-aventis Group (EUROTEXT: SAN), (NYSE: SNY), announced today the acceptance of a Biologics Licensing Application (BLA) by the U.S. Food and Drug Administration (FDA) for PENTACEL™ vaccine, a pediatric combination vaccine candidate that targets diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type b (Hib). Sanofi pasteur to complete influenza vaccine shipments ahead of schedule. www.sanofipasteur.us /sanofi-pasteur-us/front/pages/vaccination-immunology-vaccines-aventis-pasteur.jsp   (179 words)

Sanofi Aventis Company Information listing information - BioView Aventis Pharmaceuticals is proud to be an equal opportunity employer committed to a diverse workforce. Aventis focuses on prescription drugs for important therapeutic areas such as oncology, cardiology, diabetes, respiratory/allergy, anti-infectives as well as on human vaccines. Aventis (NYSE: AVE) is dedicated to improving life by treating and preventing human disease through the discovery and development of innovative pharmaceutical products. www.bioview.com /bv/servlet/BVCompanyDetails;jsessionid=8C2C48DAD331F0862DC46A8D1C11699C?ID=164467   (279 words)

Morningstar - Dow Jones & Company, Inc.: UPDATE: Bristol-Myers, Sanofi-Aventis Reach Plavix Settlement Bristol and Sanofi noted in their statement that a loss of market exclusivity for Plavix "could be material to Sanofi-Aventis' and Bristol-Myers Squibb's financial condition and liquidity." Bristol and Sanofi also advised that it was possible that their agreement with Apotex may not be cleared by antitrust regulators. Bristol and Sanofi are also locked in litigation with Indian generic drugmaker Dr. news.morningstar.com /news/DJ/M03/D21/200603211840DOWJONESDJONLINE000820.html?djnsection=DJN2   (469 words)

Sanofi-aventis Provides Relief to Hurricane Victims Sanofi-aventis quickly mobilized to provide these employees financial aid in the form of payroll advances, along with temporary housing assistance and the company is working to provide alternative work assignments for those field-based employees whose territories were severely affected by Hurricane Katrina. In addition, tens of thousands of doses of tetanus vaccine have been donated for use by victims and emergency responders as well as a variety of pediatric vaccines that had been lost due to the severe flooding conditions. Nearly 20,000 additional vials of Lantus have also been delivered recently to the disaster area through bulk and much needed individual shipments, and the company is continuing to receive and fulfill requests on a daily basis. www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-29-2005/0004134703&EDATE=   (560 words)

Sanofi-Aventis Trips in Court Although the court's ruling is a setback for Sanofi-Aventis, the legal process and the FDA review will take a long time, says Tim Anderson of Prudential Equity Group. The stay has been in effect since the former Aventis filed patent infringement suits against both companies in August 2003. If the decision stands, the court would lift a 30-month stay against Amphastar and Teva Pharmaceutical Industries (TEVA:Nasdaq ADR - commentary - research), which are both trying to sell generic copies of Lovenox. thestreet.com /_googlen/stocks/robertsteyer/10228453.html?...&cm_ite=NA   (314 words)

globeandmail.com : globeinvestor.com : Sanofi-aventis Statement Jean-Francois Dehecq stated that he had already indicated that "Rhodia is not a strategic investment for sanofi-aventis and as a result, sanofi- aventis does not intend to sit on Rhodia's board of directors." In this connection, the company recalls the high visibility given not just to the union of Sanofi-Synthelabo and Aventis but also to Rhodia's particular situation as well as to several disputes between the two companies. This principle was subsequently repeated in the information prospectus prepared in late 2004 for the merger between sanofi-aventis and Aventis: www.globeinvestor.com /servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20050603&archive=prnews&slug=2005_06_03_12_5901_1383321   (379 words)

Sanofi-Aventis Customer Service - News Items The sanofi-aventis Group conducts its business in the United States through its subsidiaries Aventis Pharmaceuticals is announcing effective September 13, 2004, Lantus® (insulin glargine [rDNA origin] injection) will be shipped in new refrigerated packaging via UPS ground transportation when possible. However, if the destination cannot be reached by UPS ground 2nd-day delivery, then Aventis will ship via UPS Air 2nd-day delivery. www.aventis.custservices.com /news.asp?up=219   (290 words)

Better Investing - sanofi-aventis The sanofi-aventis Group (Euronext Paris:SAN; NYSE:SNY) was formed by the 2004 merger of Sanofi-Synthelabo and Aventis, which created Europe's largest pharmaceutical company and the third largest pharmaceutical company in the world. Lauscher was based in Strasbourg, France and served as the key contact for European investors and analysts at Aventis (now part of the sanofi-aventis Group following the 2004 merger with Sanofi-Synthelabo), before moving to New York in 2001. Sanofi-aventis is focused on treating five major therapeutic areas: cardiovascular/thrombosis, oncology, central nervous system, diabetes and internal medicine. www.betterinvesting.org /articles/web/9559   (282 words)

WebWire® News Website Can Keep Domain Name After Trademark Fight Under terms of Tuesday’s settlement, AcompliaReport.com keeps its domain name, as long as there is a disclaimer stating that the website is not associated with Sanofi-Aventis. "Sanofi’s tactics threatened to quash free and accurate speech," said EFF staff attorney Corynne McSherry. And basic First Amendment principles barred Sanofi from using trademark law to shut down an independent news site." www.webwire.com /ViewPressRel.asp?aId=5437   (307 words)

Sanofi-Aventis ADR Stock Report (SNY) Quote & News Sanofi-Aventis was formed by a merger of two France-based pharmaceutical companies, Sanofi-Synthelabo and Aventis, creating the world's third-largest pharmaceutical firm. Sanofi: Appeals Court Rules For Co. In Lovenox Patent Case (DJ) PULSE: Sanofi: Appeals court rules for co. in Lovenox patent case (MW) quote.morningstar.com /Switch.html?ticker=SNY   (273 words)

Try your search on: Qwika (all wikis)

About us   |   Why use us?   |   Reviews   |   Press   |   Contact us   Copyright © 2005-2007 www.factbites.com Usage implies agreement with terms.